Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer
2023-505898-32-00Phase 2Authorised
- Sponsor
- Celcuity Inc.
- Start
- Jan 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of gedatolisib and darolutamide in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Celcuity Inc. Primary endpoints: Safety and laboratory abnormalities, BOIN utility score and 2 more. Planned start Jan 2024; status: authorised.
02
Drugs
gedatolisibdarolutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2023-505898-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505898-32-00.